Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea and Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation.

Trial Profile

Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea and Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Nov 2008 Planned end date changed to 1 Oct 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top